Literature DB >> 15534177

Neuromuscular disorders in severe acute respiratory syndrome.

Li-Kai Tsai1, Sung-Tsang Hsieh, Chi-Chao Chao, Yee-Chun Chen, Yea-Huey Lin, Shan-Chwen Chang, Yang-Chyuan Chang.   

Abstract

OBJECTIVE: To delineate and clarify neuromuscular disorders in patients with probable severe acute respiratory syndrome (SARS).
DESIGN: Case series with follow-up ranging from 3 weeks to 2 months.
SETTING: National Taiwan University Hospital, Taipei. PATIENTS: We investigated 4 patients with SARS who had concomitant neuromuscular problems. A diagnosis of SARS was based on the demonstration of serum coronavirus antibodies. Clinical presentations, laboratory results, electrophysiologic findings, and follow-up conditions were determined.
RESULTS: Patients developed neuromuscular problems approximately 3 weeks after the onset of SARS. Two women experienced motor-predominant peripheral nerve disorders. A man developed myopathy and a third woman experienced neuropathy and myopathy. Cerebrospinal fluid obtained from 2 patients with neuropathy disclosed normal protein content and the absence of pleocytosis and SARS coronavirus antibodies. Both patients with myopathy had elevated serum creatine kinase levels. A rapid clinical and electrophysiologic improvement was evident during follow-up examinations, with a good prognosis.
CONCLUSIONS: The neuromuscular problems in patients with SARS are considered to be critical-illness polyneuropathy or myopathy, possibly coexistent. Further pathological and microbiological studies are necessary to determine the relationship between SARS coronavirus and neuromuscular problems.

Entities:  

Mesh:

Year:  2004        PMID: 15534177     DOI: 10.1001/archneur.61.11.1669

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  100 in total

Review 1.  Pathology and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Authors:  Henok Kessete Afewerky
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-07

2.  Neuromusculoskeletal disorders following SARS: a case series.

Authors:  Brynne Stainsby; Scott Howitt; Jason Porr
Journal:  J Can Chiropr Assoc       Date:  2011-03

Review 3.  Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.

Authors:  Adeel S Zubair; Lindsay S McAlpine; Tova Gardin; Shelli Farhadian; Deena E Kuruvilla; Serena Spudich
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

4.  Frequency of Neurological Presentations of Coronavirus Disease in Patients Presenting to a Tertiary Care Hospital During the 2019 Coronavirus Disease Pandemic.

Authors:  Samar Iltaf; Meraj Fatima; Salma Salman; Jawwad-Us Salam; Saira Abbas
Journal:  Cureus       Date:  2020-08-18

Review 5.  Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection.

Authors:  Vincent C C Cheng; Susanna K P Lau; Patrick C Y Woo; Kwok Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

6.  Long-term sequelae following previous coronavirus epidemics.

Authors:  Oliver O'Sullivan
Journal:  Clin Med (Lond)       Date:  2020-11-03       Impact factor: 2.659

Review 7.  Nervous System Involvement in COVID-19: a Review of the Current Knowledge.

Authors:  Mahnaz Norouzi; Paniz Miar; Shaghayegh Norouzi; Parvaneh Nikpour
Journal:  Mol Neurobiol       Date:  2021-03-25       Impact factor: 5.590

Review 8.  Potential Neurologic Manifestations of COVID-19.

Authors:  Anna S Nordvig; Kathryn T Fong; Joshua Z Willey; Kiran T Thakur; Amelia K Boehme; Wendy S Vargas; Craig J Smith; Mitchell S V Elkind
Journal:  Neurol Clin Pract       Date:  2021-04

9.  Disaster Neurology Update: Focus on the COVID-19 Pandemic.

Authors:  Jayaji M Moré; Justin A Miller; Mill Etienne
Journal:  Neurol Clin Pract       Date:  2021-04

Review 10.  Neurological pathogenesis of SARS-CoV-2 (COVID-19): from virological features to clinical symptoms.

Authors:  Yoshitaka Kase; Hideyuki Okano
Journal:  Inflamm Regen       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.